Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

Sang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, Hun Mo Ryoo, Joo Seop Chung, Young Don Joo, Soo Mee Bang, Chul Won Jung, Dong Hwan Kim, Sung Soo Yoon, Ho In Kim, Hong Ghi Lee, Jong Ho Won, Yoo Hong Min, June Won Cheong, Joon Seong Park, Ki Seong Eom, Myung Soo Hyun, Min Kyoung Kim, Hawk KimMoo Rim Park, Jinny Park, Chul Soo Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Eun Kyung Park, Dae Young Zang, Deog Yeon Jo, Joon Ho Moon, Seon Yang Park

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with <1000: 80.6% vs. 19.4%; ≥1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with <1000: 3.2% vs. 96.8%; ≥1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of ≥1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).

Original languageEnglish
Pages (from-to)1024-1029
Number of pages6
JournalLeukemia and Lymphoma
Volume52
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Leukemia, Myeloid, Chronic Phase
Therapeutics
Imatinib Mesylate
Incidence

Keywords

  • Chronic myeloid leukemia
  • cytogenetic response
  • imatinib
  • molecular response
  • trough blood level

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. / Sohn, Sang Kyun; Oh, Suk Joong; Kim, Byung Soo; Ryoo, Hun Mo; Chung, Joo Seop; Joo, Young Don; Bang, Soo Mee; Jung, Chul Won; Kim, Dong Hwan; Yoon, Sung Soo; Kim, Ho In; Lee, Hong Ghi; Won, Jong Ho; Min, Yoo Hong; Cheong, June Won; Park, Joon Seong; Eom, Ki Seong; Hyun, Myung Soo; Kim, Min Kyoung; Kim, Hawk; Park, Moo Rim; Park, Jinny; Kim, Chul Soo; Kim, Hyeoung Joon; Kim, Yeo Kyeoung; Park, Eun Kyung; Zang, Dae Young; Jo, Deog Yeon; Moon, Joon Ho; Park, Seon Yang.

In: Leukemia and Lymphoma, Vol. 52, No. 6, 01.06.2011, p. 1024-1029.

Research output: Contribution to journalArticle

Sohn, SK, Oh, SJ, Kim, BS, Ryoo, HM, Chung, JS, Joo, YD, Bang, SM, Jung, CW, Kim, DH, Yoon, SS, Kim, HI, Lee, HG, Won, JH, Min, YH, Cheong, JW, Park, JS, Eom, KS, Hyun, MS, Kim, MK, Kim, H, Park, MR, Park, J, Kim, CS, Kim, HJ, Kim, YK, Park, EK, Zang, DY, Jo, DY, Moon, JH & Park, SY 2011, 'Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia', Leukemia and Lymphoma, vol. 52, no. 6, pp. 1024-1029. https://doi.org/10.3109/10428194.2011.563885
Sohn, Sang Kyun ; Oh, Suk Joong ; Kim, Byung Soo ; Ryoo, Hun Mo ; Chung, Joo Seop ; Joo, Young Don ; Bang, Soo Mee ; Jung, Chul Won ; Kim, Dong Hwan ; Yoon, Sung Soo ; Kim, Ho In ; Lee, Hong Ghi ; Won, Jong Ho ; Min, Yoo Hong ; Cheong, June Won ; Park, Joon Seong ; Eom, Ki Seong ; Hyun, Myung Soo ; Kim, Min Kyoung ; Kim, Hawk ; Park, Moo Rim ; Park, Jinny ; Kim, Chul Soo ; Kim, Hyeoung Joon ; Kim, Yeo Kyeoung ; Park, Eun Kyung ; Zang, Dae Young ; Jo, Deog Yeon ; Moon, Joon Ho ; Park, Seon Yang. / Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 6. pp. 1024-1029.
@article{6b0eea2ebb924ce1b0085bbc34b8a3b9,
title = "Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia",
abstract = "To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7{\%}) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with <1000: 80.6{\%} vs. 19.4{\%}; ≥1000: 94.6{\%} vs. 5.4{\%}; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with <1000: 3.2{\%} vs. 96.8{\%}; ≥1000: 21.4{\%} vs. 78.6{\%}; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of ≥1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).",
keywords = "Chronic myeloid leukemia, cytogenetic response, imatinib, molecular response, trough blood level",
author = "Sohn, {Sang Kyun} and Oh, {Suk Joong} and Kim, {Byung Soo} and Ryoo, {Hun Mo} and Chung, {Joo Seop} and Joo, {Young Don} and Bang, {Soo Mee} and Jung, {Chul Won} and Kim, {Dong Hwan} and Yoon, {Sung Soo} and Kim, {Ho In} and Lee, {Hong Ghi} and Won, {Jong Ho} and Min, {Yoo Hong} and Cheong, {June Won} and Park, {Joon Seong} and Eom, {Ki Seong} and Hyun, {Myung Soo} and Kim, {Min Kyoung} and Hawk Kim and Park, {Moo Rim} and Jinny Park and Kim, {Chul Soo} and Kim, {Hyeoung Joon} and Kim, {Yeo Kyeoung} and Park, {Eun Kyung} and Zang, {Dae Young} and Jo, {Deog Yeon} and Moon, {Joon Ho} and Park, {Seon Yang}",
year = "2011",
month = "6",
day = "1",
doi = "10.3109/10428194.2011.563885",
language = "English",
volume = "52",
pages = "1024--1029",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

AU - Sohn, Sang Kyun

AU - Oh, Suk Joong

AU - Kim, Byung Soo

AU - Ryoo, Hun Mo

AU - Chung, Joo Seop

AU - Joo, Young Don

AU - Bang, Soo Mee

AU - Jung, Chul Won

AU - Kim, Dong Hwan

AU - Yoon, Sung Soo

AU - Kim, Ho In

AU - Lee, Hong Ghi

AU - Won, Jong Ho

AU - Min, Yoo Hong

AU - Cheong, June Won

AU - Park, Joon Seong

AU - Eom, Ki Seong

AU - Hyun, Myung Soo

AU - Kim, Min Kyoung

AU - Kim, Hawk

AU - Park, Moo Rim

AU - Park, Jinny

AU - Kim, Chul Soo

AU - Kim, Hyeoung Joon

AU - Kim, Yeo Kyeoung

AU - Park, Eun Kyung

AU - Zang, Dae Young

AU - Jo, Deog Yeon

AU - Moon, Joon Ho

AU - Park, Seon Yang

PY - 2011/6/1

Y1 - 2011/6/1

N2 - To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with <1000: 80.6% vs. 19.4%; ≥1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with <1000: 3.2% vs. 96.8%; ≥1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of ≥1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).

AB - To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with <1000: 80.6% vs. 19.4%; ≥1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with <1000: 3.2% vs. 96.8%; ≥1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of ≥1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).

KW - Chronic myeloid leukemia

KW - cytogenetic response

KW - imatinib

KW - molecular response

KW - trough blood level

UR - http://www.scopus.com/inward/record.url?scp=79957452443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957452443&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.563885

DO - 10.3109/10428194.2011.563885

M3 - Article

C2 - 21463107

AN - SCOPUS:79957452443

VL - 52

SP - 1024

EP - 1029

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -